Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 269

The DOI matches its Crossref record.

Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia

Kinon, Bruce J., Basson, Bruce R., Gilmore, Julie A., Tollefson, Gary D.·2001·The Journal of Clinical Psychiatry

Abstract

Article AbstractBackground: Weight change and the weight-relatedhealth factors of nonfasting serum glucose, serum cholesterol,and diastolic blood pressure levels were analyzed in patientswith DSM-III-R schizophrenia and related disorders who receivedtreatment with olanzapine for up to 3 years, and comparisons weremade to patients treated with haloperidol. Baseline body massindex (BBMI; kg/m2) and dose (mg/day) wereinvestigated as predictors of long-term weight change experiencedduring olanzapine treatment. Method: This analysis retrospectively examined573 patients receiving olanzapine and 103 patients receivinghaloperidol for 39 weeks or more from a study of 1996 patientsrandomly assigned 2:1 to either olanzapine, 5 to 20 mg/day, orhaloperidol, 5 to 20 mg/day. After 6 weeks of acute therapy,patients continued for 1 year or more with either double-blind oropen-label olanzapine therapy or double-blind haloperidoltherapy. Results: Mean weight gain for olanzapine-treatedpatients observed for a median of 2.54 years trended toward aplateau after the first 39 weeks of treatment with alast-observation-carried-forward mean weight change of 6.26 kg(13.8 lb) and a median of 5.90 kg (13.0 lb). This wassignificantly higher than that for haloperidol-treated patients,whose mean weight gain was 0.69 kg (1.5 lb) after 1.15 years (p 27.6) gainedsignificantly less weight during treatment with olanzapine thantheir lighter counterparts (BBMI < 27.6) (p =.183). Median serum glucose at endpoint was not significantlyassociated (p = .096) with weight change for olanzapine. Medianserum cholesterol and diastolic blood pressure forolanzapine-treated patients at endpoint showed a relationshipwith weight change that was statistically (p .05). Conclusion: Mean weight gain duringolanzapine treatment trended toward a plateau after theinitial 39 weeks of treatment with no further significant gainout to 3 years. Higher BBMI was predictive of a lower long-termweight gain, while dose was not a significant predictor ofgreater longer term weight change. The relationship betweenweight change and glucose was not statistically significant. Theassociation between weight change and changes in cholesterol aswell as changes in diastolic blood pressure was statisticallysignificant but not considered clinically relevant based on theranges observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v62n0204

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 269

Metadata

Authors
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D.
Venue
The Journal of Clinical Psychiatry
Published
2001-02-15
Volume
62
Issue
2
Pages
92-100
ISSN
0160-6689 (ISSN-L)
OpenAlex
W4294235448
Cited by
269
References
0
FWCI
14.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia. https://app.cochat.ai/papers/10.4088/jcp.v62n0204
The paper
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001). Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v62n0204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.